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Data collection and analysis
We used standard methods of Cochrane and its Childhood Cancer Group. Two independent review authors performed study selection, data extraction, and risk of bias assessment. We entered data extracted from the included studies into Review Manager 5 and undertook analyses according to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions.
Main results
We included two randomized controlled trials assessing very early, early, non-early (or a combination of these) discharge in children with cancer and febrile neutropenia. We graded the evidence as low quality; we downgraded for risk of bias and imprecision. One study, Santolaya 2004, consisted of 149 randomized low-risk episodes and compared early discharge (mean/median of less than five days) to non-early discharge (mean/median of five days or more). This study found no clear evidence of difference in treatment failure (risk ratio (RR) 0.91, 95% confidence interval (CI) 0.24 to 3.50, P value = 0.89 for rehospitalization or adjustment of antimicrobial treatment, or both; Fischer's exact P value = 0.477 for death) or duration of treatment (mean difference -0.3 days, 95% CI -1.22 to 0.62, P value = 0.52 for any antimicrobial treatment; mean difference -0.5 days, 95% CI -1.36 to 0.36, P value = 0.25 for intravenous antimicrobial treatment; mean difference 0.2 days, 95% CI -0.51 to 0.91, P value = 0.58 for oral antimicrobial treatment). Costs were lower in the early discharge group (mean difference USD -265, 95% CI USD -403.14 to USD -126.86, P value = 0.0002). The second included study, Brack 2012, consisted of 62 randomized low-risk episodes and compared very early discharge (mean/median of less than 24 hours) to early discharge (mean/median of less than five days). This study also found no clear evidence of difference in treatment failure (RR 0.54, 95% CI 0.15 to 1.89, P value = 0.34 for rehospitalization or adjustment of antimicrobial treatment (or both); Fischer's exact P value = 0.557 for death). Regarding duration of treatment, median duration of intravenous antimicrobial treatment was shorter in the very early discharge group (Wilcoxon's P value ≤ 0.001, stated in the study) and median duration of oral antimicrobial treatment was shorter in the early discharge group (Wilcoxon's P ≤ 0.001, stated in the study) as compared to one another. However, there was no clear evidence of difference in median duration of any antimicrobial treatment (Wilcoxon's P value = 0.34, stated in the study). Costs were not assessed in this study. Neither of the included studies assessed quality of life. Meta-analysis was not possible as the included studies assessed different discharge moments and used different risk stratification models.
Authors' conclusions
Very limited data were available regarding the safety of early discharge compared to non-early discharge from in-hospital treatment in children with cancer and febrile neutropenia and a low risk for invasive infection. The absence of clear evidence of differences in both studies could be due to lack of power.
Evidently, there are still profound gaps regarding very early and early discharge in children with cancer and febrile neutropenia. Future studies that assess this subject should have a large sample size and aim to establish uniform and objective criteria regarding the identification of a low-risk febrile neutropenic episode.
P L A I N L A N G U A G E S U M M A R Y

Very early discharge versus early discharge versus non-early discharge in children with cancer and fever during neutropenia
Review question
In this review of the literature we aimed to determine whether early discharge (less than five days, on average) from in-hospital treatment, for a selected group of children, is not inferior to non-early discharge (five days or more, on average) in children with cancer and fever during neutropenia. Furthermore, we wanted to evaluate whether very early discharge (less than 24 hours, on average) is not inferior to early discharge, and whether very early discharge is not inferior to non-early discharge.
Background
Treatment with chemotherapy can cause a low white blood cell count (neutropenia) in children with cancer. Due to the high risk of bacterial infections and of a sudden and severe course of infections, standard care for children with cancer and fever during neutropenia consists of routine hospitalization and intravenous administration of broad-spectrum antibiotics (antibiotics that act against a wide range of disease-causing bacteria). However, causes of fever during neutropenia can be less serious; in a subgroup of these children lengthy in-hospital treatment might be unnecessary.
Outcomes
Illustrative comparative risks* (95% CI) Relative effect (95% CI) 
No of episodes (studies)
Quality
Quality of life
Not assessed Not assessed --Not estim able No inf orm ation on quality of lif e was provided * The basis f or the assumed risk (e.g. the m edian control group risk across studies) is provided in f ootnotes. The corresponding risk (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI). CI: conf idence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the estim ate of ef f ect. M oderate quality: Further research is likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and m ay change the estim ate. Low quality: Further research is very likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and is likely to change the estim ate. Very low quality: We are very uncertain about the estim ate.
1 There were no deaths in the early discharge group and one death in the non-early discharge group (Fischer's exact P value = 0.477). 2 We downgraded the level of evidence one level because of an unclear risk of bias that lowered our conf idence in the estim ate of ef f ect (i.e. high risk of perf orm ance bias and unclear risk of selection bias, detection bias, attrition bias and reporting bias). In addition, we downgraded the level of evidence one level because of im precision (dichotom ous outcom e did not m eet their ''rule of thum b'' threshold, i.e. total num ber of events was f ewer than 300, and continuous outcom es did also not m eet their ''rule of thum b'' threshold, i.e. total num ber of participants was f ewer than 400).
B A C K G R O U N D
Description of the condition
Survival rates for children with cancer have improved substantially in recent decades (O'Leary 2008). This has been attributed to better understanding of the disease, improvement of treatment protocols and optimalization of supportive care. However, cancer treatment also has unwanted adverse effects. One of the most important adverse effects in children with cancer is chemotherapyinduced neutropenia, a haematological disorder characterized by an abnormally low number of neutrophils (type of granulocytes; category of white blood cells). In 1966, it was shown that low numbers of granulocytes were associated with an increased risk of severe infections (Bodey 1966). Due to the high relative risk of infections and infectious complications, standard care for children with cancer and febrile neutropenia (severe neutropenia with fever) consists of routine hospitalization and parenteral administration of broad-spectrum antibiotics. Children are considered eligible for discharge from in-hospital treatment when they are afebrile, have completed their antibiotic course, their absolute neutrophil count is recovering or has recovered, or a combination of these.
Description of the intervention
In 2002, the Infectious Diseases Society of America published a clear protocol for early discharge in adult with cancer and febrile neutropenia (Hughes 2002). A weighted scoring index for identification of adult low-risk febrile neutropenia at time of presentation with fever comprised extent of illness, presence of hypotension, presence of chronic obstructive pulmonary disease, presence of solid tumor, presence of fungal infection, presence of dehydration, outpatient location of onset of fever and age. A recent review focussed on the effects and applicability of this weighted scoring index after 10 years of use (Klastersky 2013). This review concluded that the weighted scoring index has been validated in several studies as a reliable tool for identifying low-risk febrile neutropenia episodes in adult cancer patients and is shown to be part of the selection process of patients who can safely be treated at home. However, early discharge of pediatric patients was a more delicate topic; it was stated that after a minimum of 48 hours of in-hospital treatment with parenteral antibiotics and observation, early discharge with oral antibiotics might be considered for selected children at low risk of bacterial infections (Hughes 2002 1997) . In this review, we have compared early discharge (mean/ median of less than five days) from in-hospital treatment to nonearly discharge (mean/median of five days or more) from in-hospital treatment, very early discharge (mean/median of less than 24 hours) from in-hospital treatment to early discharge (mean/ median of less than five days) from in-hospital treatment, and very early discharge (mean/median of less than 24 hours) from in-hospital treatment to non-early discharge (mean/median of five days or more) from in-hospital treatment in children with cancer and febrile neutropenia, and evaluated the effects on treatment failure. The main importance was to gather and share the evidence in safety of non-early discharge versus early and very early discharge and moreover, that unnecessary non-early discharge might lead, for example, to unnecessary occupation of hospital beds, increased bacterial resistance, reduced quality of life and increased healthcare costs.
O B J E C T I V E S
To evaluate whether early discharge (mean/median of less than five days) from in-hospital treatment was not inferior to nonearly discharge (mean/median of five days or more) and whether very early discharge (mean/median of less than 24 hours) was not inferior to early discharge, non-early discharge, or a combination of these, in children with cancer and febrile neutropenia.
Types of studies
Randomized controlled trials and controlled clinical trials.
Types of participants
Children with cancer under 21 years of age, presenting with febrile neutropenia. We defined neutropenia as an absolute neutrophil count less than 0.5 x 10 9 cells/L, or a leukocyte count less than 1.0 x 10 9 cells/L (when an absolute neutrophil count was not available). We defined fever as a single oral reading of greater than 38.2°C or two readings of a temperature greater than 37.9°C within 24 hours.
Types of interventions
We defined:
• non-early discharge as discharge from in-hospital treatment after (a mean or median of ) at least five days;
• early discharge as discharge from in-hospital treatment (with a mean or median of ) less than five days after presentation with fever and neutropenia;
• very early discharge as discharge from in-hospital treatment (with a mean or median of ) less than 24 hours after presentation with fever and neutropenia.
We planned to include studies that compared the following in children with cancer and febrile neutropenia at low risk of invasive bacterial infection:
• early discharge from in-hospital treatment versus non-early discharge from hospital treatment;
• very early discharge from in-hospital treatment versus nonearly discharge from hospital treatment;
• very early discharge from in-hospital treatment versus early discharge from hospital treatment.
Types of outcome measures Primary outcomes
• Treatment failure:
• rehospitalization or adjustment of antimicrobial treatment (or both) related to febrile neutropenia (participant deterioration or other febrile neutropenia-related causes), within one week or within the same neutropenic episode;
• all death and death due to (complications of ) febrile neutropenia within one week after hospital discharge or within the same neutropenic episode after hospital discharge.
Secondary outcomes
• Quality of life.
• Costs.
• Duration of antimicrobial treatment:
• duration of total antimicrobial treatment;
• duration of intravenous antimicrobial treatment;
• duration of oral antimicrobial treatment.
Search methods for identification of studies
See: Cochrane Childhood Cancer Group methods used in reviews (Module CCG). We imposed no language restrictions. We will update the searches every two years.
Electronic searches
We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (2015; Issue 11), MEDLINE/PubMed (from 1945 to 9 December 2015) and EM-BASE/Ovid (from 1980 to 9 December 2015). The appendices show the search strategies for the different electronic databases (using a combination of controlled vocabulary and text words) (Appendix 1; Appendix 2; Appendix 3).
Searching other resources
We located information about trials not registered in CENTRAL, MEDLINE or EMBASE, either published or unpublished, by searching the reference lists of relevant articles and review articles. After employing the search strategy described above, two review authors independently identified studies meeting the inclusion criteria. We resolved discrepancies between review authors by consensus. If this had been impossible, we planned to achieve final resolution by using a third party arbitrator. However, this was not necessary. We obtained the full-text reports of any study that seemed to meet the inclusion criteria on the grounds of the title, abstract, or both, for closer inspection. Regarding the studies excluded after closer inspection, we stated the reasons for exclusion in the Characteristics of excluded studies table.
Data extraction and management
Two review authors independently performed data extraction using standardized forms. We extracted data on the following items.
• Study design.
• Participants, including:
• number of children entering the trial;
• number of children randomized;
• number of children excluded (with reasons);
• number of children evaluable (for each outcome);
• degree of neutropenia at the moment of presentation with febrile neutropenia.
• Intervention: duration of admittance to the hospital in hours/days until discharge from in-hospital treatment. Inhospital treatment: no, oral or intramuscular/intravenous antibiotic treatment. Treatment after discharge: no, oral or intramuscular/intravenous antibiotic treatment.
• Outcome measures.
• Length of follow-up.
When data were missing in a published report, we attempted to contact the authors for the missing information. This was the case in one of the included studies (Brack 2012), as is stated below ( Dealing with missing data). In cases of disagreement regarding data extraction, we planned to re-examined the abstracts and articles and undertake discussion until we achieved consensus. If this was impossible, we planned to achieve final resolution using a third party arbitrator. However, this was not necessary.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of the included randomized controlled trials, according to the following criteria:
• random sequence generation;
• concealment of allocation;
• blinding of care provider/participants/outcome assessors;
• incomplete outcome data;
• selective reporting;
• other bias, specifically baseline imbalance (e.g. due to selective randomization), differential diagnostic activity (e.g. due to other follow-up programmes for different discharge moments) and selective reporting of subgroups.
For the quality items, we used the definitions as described in the module of the Childhood Cancer Group, based on the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011; Module CCG). We resolved discrepancies between review authors by consensus. If this was impossible, we planned to achieve final resolution using a third party arbitrator. However, this was not necessary. In the analyses, we took the quality of study into account in the interpretation of the review results.
Measures of treatment effect
We entered data into Review Manager 5 (RevMan 2012) and undertook analyses according to the guidelines of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We analyzed dichotomous variables using risk ratios (RR). We analyzed continuous outcomes using the mean difference (MD). We presented results with the corresponding 95% confidence interval (CI). For outcomes where only one study was available, we were unable to calculate an RR if one of the treatment groups experienced no events and we used the Fischer's exact test instead (using SPSS 20.0 (IBM Corp., Armonk, NY, USA)).
Dealing with missing data
When information relevant to study selection, data extraction, assessment of risk of bias, or a combination of these was missing, we attempted to contact the authors in order to obtain the missing data. We contacted the authors of one of the included studies because their definition of the outcome treatment failure was slightly different from ours (i.e. in addition to rehospitalization or adjustment of antimicrobial therapy (or both) and death (our definition of treatment failure), in the included study fever greater than 48 hours, bacteraemia, persistent symptoms and signs of local infection or addition of antifungal therapy (or both) were also considered as treatment failure) (Brack 2012). We asked the authors to specify the reasons for treatment failure of all episodes of which the reason was not stated specifically or clearly (or both) in the full-text article. They responded swiftly and provided the requested data. We planned to perform intention-to-treat analyses. In Brack 2012, it was clear that the intention-to-treat principle was used, therefore we performed intention-to-treat analyses of these data. However, in Santolaya 2004, it was not explicitly described whether or not the intention-to-treat principle was used (although it seems to be done), so we were unable to do this.
Assessment of heterogeneity
In the protocol, we stated that we would assess heterogeneity both by visual inspection of the forest plots and by a formal statistical test for heterogeneity, the I 2 statistic. In the absence of substantial heterogeneity (I 2 less than 50%) (Higgins 2011), we wanted to use a fixed-effect model for the estimation of treatment effects. Otherwise, we wanted to explore possible reasons for the occurrence of heterogeneity and take appropriate measures by using the random-effects model. However, since we could not pool the data from the included studies, this was not applicable.
Assessment of reporting biases
In the protocol, we stated that we would construct a funnel plot to ascertain the risk of publication bias graphically (Higgins 2011). However, since we could not pool the data from the included studies, this was not applicable.
Data synthesis
In the protocol, we stated that when possible we would analyze data for different types of malignancies. Due to lack of information, this was not possible. We included outcome measures in this systematic review only if it was the intention of the study to perform the necessary assessments in all participants (i.e. not optional or only performed in some centres). When less than 50% of the participants of a study had an acceptable follow-up for a particular outcome measure, due to the associated high risk of attrition bias, we planned not to report the results of this outcome measure. However, since in Santolaya 2004 there were no episodes lost to follow-up and in Brack 2012 there was one out of 62 episodes lost to follow-up, this was not applicable. If pooling was not possible, we summarized the results qualitatively. For each comparison. we prepared when possible a 'Summary of findings' table using the GRADEpro software in which we presented the following outcomes: treatment failure (i.e. rehospitalization or adjustment of antimicrobial treatment (or both), and death), quality of life, costs and duration of antimicrobial treatment (i.e. total, intravenous and oral). However, in Summary of findings 2 (very early discharge versus early discharge), we divided treatment failure into three outcomes (i.e. rehospitalization or adjustment of antimicrobial treatment in number of episodes (or both) and in number of participants, and death). Two review authors independently assessed the quality of the evidence using the five GRADE considerations (i.e. study limitations, inconsistency, indirectness, imprecision and publication bias).
Subgroup analysis and investigation of heterogeneity
In the protocol, we stated that when possible we would perform subgroup analyses. However due to lack of information or lack of stratified data subgroup analyses were not possible. We planned to analyze:
• in-hospital treatment:
• in-hospital treatment with intravenous or intramuscular antibiotics versus oral antibiotics;
• in-hospital treatment with intravenous or intramuscular antibiotics versus no antibiotics;
• in-hospital treatment with oral antibiotics versus no antibiotics;
• treatment after discharge:
• treatment after discharge with intravenous or intramuscular antibiotics versus oral antibiotics;
• treatment after discharge with intravenous or intramuscular antibiotics versus no antibiotics;
• treatment after discharge with oral antibiotics versus no antibiotics;
• age: birth to under four years versus four to less than 21 years;
• type of malignancy: haematological malignancies versus solid tumours;
• degree of neutropenia at the moment of presentation with febrile neutropenia; absolute neutrophil count of 0.1 to 0.5 x 10 9 cells/L versus less than 0.1 x 10 9 cells/L.
Sensitivity analysis
In the protocol, we stated that we wanted to perform a sensitivity analysis; however, this was not possible or applicable (or both). Regarding the individual risk of bias criteria, it was not possible to perform sensitivity analyses considering the fact that pooling was not possible. The search strategy identified 590 references in the three electronic databases, of which we evaluated 12 studies as full text as potential studies for inclusion. Two of these fulfilled all criteria for inclusion in this review and were thus included (Brack 2012; Santolaya 2004). We excluded the other 10 studies for reasons stated in the Characteristics of excluded studies table. We excluded all other studies based on title or abstract, since they were not randomized controlled trials or controlled clinical trials, did not include children, did not include children with cancer, defined fever otherwise than described in our inclusion criteria or defined neutropenia otherwise than described in our inclusion (or both). The search performed on the conference proceedings, reference lists of reviews and the reference lists of the included studies identified 30 additional studies. We excluded all references based on title and abstract, for same reasons as described in the initial database search. In the latest search for ongoing trials, we searched the registries of ISRCTN (www.ISRCTN.com), National Institutes of Health (NIH) (clinicaltrials.gov) and WHO ICTRP (apps.who.int/ trialsearch/) in January 2016): we identified no relevant ongoing trials.
Included studies
For inclusion in this review, only children with fever during neutropenia at low risk for invasive bacterial infection were eligible. Santolaya 2004 was a randomized controlled trial that compared outcome and costs of early discharge versus non-early discharge among children with fever during neutropenia at low risk for invasive bacterial infection. A total of 390 episodes of febrile neutropenia occurred in 313 children with cancer; 168 episodes were classified as low-risk at enrolment. After the second assessment of the low-risk children, five children appeared to be high risk; they were excluded from the study. Of the 161 episodes at low-risk for invasive bacterial infection, 12 (41%) could not be randomized due to various reasons. The remaining 149 episodes in 107 children were randomly assigned in parallel groups after 24 to 36 hours of hospitalization to receive ambulatory (78 children) or hospital-based (71 children) treatment and they were monitored until episode resolution. Antibiotic treatment consisted of intravenous ceftriaxone and teicoplanin. Intravenous antibiotic treatment was switched to oral cefuroxime after a minimum of 72 hours when the clinical evolution was favourable. Outcome and costs were determined for each episode and compared between both groups using pre-defined definitions and questionnaires. Brack 2012 was a randomized controlled trial that investigated safety and efficacy of very early discharge versus early discharge among children with fever during neutropenia at low risk for invasive bacterial infection. All included children were re-assessed after eight to 22 hours of inpatient therapy. Children then identified with low-risk febrile neutropenia were randomized to either very early discharge (mean/median of less than 24 hours) or early discharge (continued inpatient therapy for more than 24 hours with a median of four days). A total of 355 potentially eligible episodes of febrile neutropenia occurred, of which 93 (26%) fulfilled low-risk criteria at re-assessment after eight to 22 hours of inpatient therapy. Of these, informed consent for randomization was declined in 25 (27%) episodes, and randomization was not performed for unknown reasons in six (6%) episodes. Thus, 62 (67%) low-risk episodes in 52 children (eight children with two episodes, one child with three episodes) were randomized to very early discharge (28 children, one lost to follow-up) or early discharge (34 children). All children but one (lost to follow-up; centre stopped study participation) were monitored until antimicrobial therapy had been stopped for at least seven days and severe neutropenia had resolved. All children were initially treated with empirical intravenous broad-spectrum antimicrobial therapy. In episodes randomized to early discharge, intravenous antimicrobial therapy was continued, in episodes randomized to very early discharge, intravenous antimicrobial therapy was replaced by a combination of oral ciprofloxacin and oral amoxicillin. Outcomes regarding safety and efficacy were determined for each episode and compared between both groups using pre-defined definitions. For more information, see the Characteristics of included studies table.
Excluded studies
After full-text review, we excluded 10 studies that initially appeared to be potential for inclusion based on same discharge moment in both groups (four studies), adult study (two studies), moment of discharge not reported (three studies) and article was a commentary (one study). In Santolaya 2004, there was an unclear risk of selection bias (based on random sequence generation and allocation concealment), a high risk of performance bias (based on lack of blinding of participants and personnel), an unclear risk of detection bias (based on blinding of outcome assessment) for all reported outcomes, an unclear risk of attrition bias (based on incomplete outcome data), an unclear risk of reporting bias (based on selective reporting) and a low risk of other bias (no other risk of bias identified, clear explanation of not performed randomizations). In Brack 2012, there was an unclear risk of selection bias (based on a low risk of random sequence generation, but an unclear risk of allocation concealment), a high risk of performance bias (based on lack of blinding of participants and personnel), an unclear risk of detection bias (based on blinding of outcome assessment) for all reported outcomes, a low risk of attrition bias (based on incomplete outcome data), an unclear risk of reporting bias (based on selective reporting) and a high risk of other bias (based on a high risk of baseline imbalance due to lack of explanation of declined and not performed randomizations in 25 (declined) and six (not performed) of 93 episodes 
Risk of bias in included studies
Early discharge versus non-early discharge
One study compared early discharge versus non-early discharge (Santolaya 2004).
Primary outcomes
Rehospitalization or adjustment of antimicrobial treatment (or both)
The study stated that rehospitalization or adjustment of antimicrobial treatment, or both, within the same neutropenic episode, occurred in 4 out of the 78 episodes (5%) in the early discharge group and in 4 out of the 71 episodes (6%) in the non-early discharge group (RR 0.91; 95% CI 0.24 to 3.50, P value = 0.89) (Figure 3) . 
Death
The study stated that there were no deaths due to complications of febrile neutropenia within the same neutropenic episode in the early discharge group. There was one death in the non-early discharge group (Fischer's exact P value = 0.477).
Secondary outcomes
Quality of life
This study did not assess the pre-defined outcome measure quality of life.
Costs
The study stated that the mean costs for early discharge treatment were significantly lower than the costs for the non-early discharge treatment (USD 638; 95% CI 572 to 703 with early discharge versus USD 903; 95% CI USD 781 to USD 1025 with nonearly discharge, stated in the study). There was an MD of USD -265.00 (95% CI -403.14 to -126.86, P value = 0.0002) when early discharge was compared to non-early discharge in favour of early discharge (Figure 4 ). 
Duration of antimicrobial treatment
• The study stated that the mean duration of antimicrobial treatment was 6.1 days (95% CI 5.4 to 6.8, stated in the study) in the early discharge group and 6.4 days (95% CI 5.9 to 7.0, stated in the study) in the non-early discharge group. The MD of early discharge compared to non-early discharge was -0.3 days (95% CI -1.22 to 0.62, P value = 0.52) ( Figure 5 ). • The mean duration of intravenous antimicrobial treatment was 4.3 days (95% CI 3.7 to 5.0, stated in the study) in the early discharge group and 4.8 days (95% CI 4.4 to 5.3, stated in the study) in the non-early discharge group. The MD of early discharge compared to non-early discharge was -0.5 days (95% CI -1.36 to 0.36, P value = 0.25) (Figure 6 ). • The mean duration of oral antimicrobial treatment was 1.8 days (95% CI 1.2 to 2.3, stated in the study) in the early discharge group and 1.6 days (95% CI 1.1 to 2.1, stated in the study) in the non-early discharge group. The MD of early discharge compared to non-early discharge was 0.2 days (95% CI -0.51 to 0.91, P value = 0.58) (Figure 7) . Subgroup analyses and sensitivity analyses were not possible or applicable, or both. Sensitivity analyses for risk of bias items were not possible. We did not perform intention-to-treat analyses as it was not explicitly described whether or not the intention-to-treat principle was used.
Very early discharge versus early discharge
One study compared very early discharge versus early discharge (Brack 2012).
Primary outcomes
Rehospitalization or adjustment of antimicrobial treatment (or both)
The study stated that rehospitalization or adjustment of antimicrobial treatment (or both), within the same neutropenic episode, occurred in 3 out of 27 episodes (11%) in the very early discharge group and in 7 out of 34 episodes (21%) in the early discharge group (RR 0.54; 95% CI 0.15 to 1.89, P value = 0.34) (Figure 8 ). In this study, the authors also performed an analysis with only the first febrile neutropenic episode of all included children. In this study, there were 61 episodes of 51 children included, thus 10 episodes were excluded. Rehospitalization or adjustment of antimicrobial treatment (or both), within the same neutropenic episode, occurred in 2 out of 24 children (8%) in the very early discharge group and in 7 out of 27 children (26%) in the early discharge group (RR 0.32; 95% CI 0.07 to 1.40, P value = 0.13) (Figure 9 ). 
Death
The study stated that there were no deaths due to complications of febrile neutropenia within the same neutropenic episode in the very early discharge group. There was one death in the early discharge group (Fischer's exact P value = 0.557).
Secondary outcomes
Quality of life
Costs
This study did not assess the pre-defined outcome costs.
Duration of antimicrobial treatment
The study reported only the median and range duration of antimicrobial treatment. Therefore, we were unable to analyse results in Review Manager 5 (RevMan 2012).
• The median duration of any antimicrobial treatment was 5 days (range 2 to 19 days, stated in the study) in the very early discharge group and 5 days (range 3 to 18 days, stated in the study) in the early discharge group (Wilcoxon's P value = 0.34, stated in the study).
• The median duration of intravenous antimicrobial treatment was 1 day (range 1 to 13 days, stated in the study) in the very early discharge group and 4.5 days (range 1 to 18 days, stated in the study) in the early discharge group (Wilcoxon's P value ≤ 0.001, stated in the study).
• The median duration of oral antimicrobial treatment was 4 days (range 0 to 14 days, stated in the study) in the very early discharge group and 0 days (range: 0 to 7 days, stated in the study) in the early discharge group (Wilcoxon's P value ≤ 0.001, stated in the study).
Subgroup analyses and sensitivity analyses were not possible or applicable, or both. Sensitivity analyses for risk of bias items were not possible.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Very early discharge versus early discharge for children with cancer and febrile neutropenia at low risk for invasive bacterial infection 
Quality of life
GRADE Working Group grades of evidence
D I S C U S S I O N Summary of main results
There were two studies that met the inclusion criteria for this review; Santolaya 2004 compared an early discharge (mean/median of less than five days) group with a non-early discharge (mean/ median of five days or more) group and Brack 2012 compared a very early discharge (mean/median of less than 24 hours) group with an early discharge (mean/median of less than five days) group. Both studies evaluated treatment failure and duration of treatment, only Santolaya 2004 evaluated costs of treatment and neither study evaluated quality of life. Regarding treatment failure, neither study identified significant differences between treatment groups in treatment failure (i.e. rehospitalization or adjustment of antimicrobial treatment (or both) and death). Regarding duration of antibiotic treatment (i.e. total, intravenous and oral antibiotics), Santolaya 2004 found no significant differences between treatment groups. Brack 2012 found significant shorter intravenous antimicrobial therapy in the very early discharge group and significantly shorter oral antimicrobial therapy in the early discharge group as compared to the other group; however, there was no significant difference in total duration of antibiotics between these groups. Santolaya 2004 found significantly lower costs in favour of the early discharge group as compared to the non-early discharge group. Subgroup analyses were not possible. Since both included studies had a relatively small number of randomized episodes (149 and 61), the non-significant differences between treatment groups of the diverse results might be because the included studies were too small to detect a difference (i.e. low power). However, the included studies did not show that early discharge of children with cancer and febrile neutropenia at low risk for invasive bacterial infection was less safe than non-early discharge, or that very early discharge of children with cancer and febrile neutropenia at low risk for invasive bacterial infection was less safe than early discharge; there were no significant differences in treatment failure between the two groups in both studies. For more information, see the Summary of findings for the main comparison and Summary of findings 2. Due to insufficient data, we prepared no 'Summary of findings' table for the comparison of very early discharge (mean/median of less than 24 hours) with non-early discharge (mean/median of five days or more).
Overall completeness and applicability of evidence
Currently there are no uniform criteria regarding identification of low-risk febrile neutropenic episodes in children with cancer. The criteria used in the included studies are shown in the Characteristics of included studies table. The main difference between the included studies was that Brack 2012 mainly used clinical parameters(e.g. focal infection and temperature), where as Santolaya 2004 also incorporated laboratory values (e.g. C-reactive protein and platelet count). With the studies using their own low-risk criteria it makes it more difficult to interpret results correctly, therefore it is of the utmost importance to establish uniform low-risk criteria. Regarding this matter, there is currently a Delphi survey being held among paediatric oncologists. Once uniform low-risk criteria have been established, these should be prospectively validated in a large study among children with cancer, as has happened in adults with cancer. At the moment, there is very little evidence available regarding early or very early discharge in children with cancer and febrile neutropenia at low risk for invasive bacterial infection. The current available evidence does not show that early discharge of children with cancer and febrile neutropenia and low risk of bacterial infection is less safe than non-early discharge, or that very early discharge of children with cancer and febrile neutropenia and low risk of bacterial infection is less safe than early discharge. In addition, one study found a significant reduction of costs for the early discharge group in comparison to the non-early discharge group. It is our opinion that, at this moment, both very early discharge and early discharge should only be practised in a trial setting in hospitals/oncology wards where close monitoring of very early and early discharged participants by well-trained employees is guaranteed.
Quality of the evidence
Both included studies were randomized controlled trials and thus qualified as high quality evidence according to the GRADE approach. However, according to factor 1 in the GRADE assessment (limitations in the design and implementation of available studies suggesting high likelihood of bias), we downgraded the level of evidence one level because of an unclear risk of bias with potential limitations that are likely to lower confidence in the estimate of effect. Both included studies showed a high risk of performance bias (based on lack of blinding of participants and personnel), as it is obvious for participants and personnel whether participants are treated inside or outside the hospital. This can cause bias as participants can report their symptoms differently because they feel unsafe having fever and not being admitted to the hospital or this could lead to underreporting symptoms as participants or their parents want them to stay at home. However, due to the clear parameters for treatment failure, this risk seems to be small. In both studies, there was an unclear risk of detection bias (based on blinding of outcome assessment) for all reported outcomes; if there was no blinding of outcome measurement this could inflict bias in favour of both treatment arms depending on the beliefs of the person handling the outcome measures. Moreover, in both studies there was an unclear risk of reporting bias (based on selective reporting) and selection bias. In addition, in Santolaya 2004, there was an unclear risk of attrition bias and a low risk of other bias, and in Brack 2012, there was a high risk of other bias (based on a high risk of baseline imbalance) and a low risk of attrition bias.
Agreements and disagreements with other studies or reviews
Since the 1990s, there has been a tendency to earlier discharge or treatment with oral or no antibiotics (or both) in people with fever and neutropenia considered to be at low risk for serious bacterial infections or infectious complications. One difference between the two risk assessment models was the moment of assessment; at presentation and after 24 to 36 hours in the study performed by Santolaya et al. and at presentation and within eight to 24 hours after admittance to the hospital in the study performed by Ammann et al. Another main difference was the parameters included in the risk assessment; the only corresponding item was platelet count. Both research groups had objective parameters. The risk assessment model used by Ammann et al. accurately predicted adverse events in their population of children with cancer. In the retrospective study performed by Miedema et al., the use of the identical risk assessment model had different sensitivity and specificity levels. This could be due to the retrospective nature of the study; however, the different treatment protocol, the different genetic background of the study population and environmental factors may also play a role. Both sets of authors stressed the necessity of prospective validation of the risk assessment score before broad clinical application and evaluation of the potential of markers of inflammation to increase its predictive performance (Ammann 2011; Miedema 2011). Criteria for unfavourable outcome in Santolaya 2004 were haemodynamic instability (not attributed to volume loss), fever after day four, re-appearance of fever after a 48-hour afebrile period persisting for at least 24 hours, an ascending C-reactive protein curve or a non-descending curve over normal limits (defined as a value greater than 40 mg/L and less than 30% decrease from a previous recording), and isolation of a bacterial pathogen from a significant sample obtained on day three, and death occurring during the febrile episode attributable to infection. In Brack 2012, criteria for unfavourable outcome were occurrence of serious medical complication (i.e. death, intensive care unit treatment, potentially lifethreatening complications as judged by the treating physician), no resolution of infection (i.e. fever 38.0°C or greater for 48 hours or longer, persistent symptoms and signs of local infection where applicable and positive control blood cultures where applicable), recurrent infection, modification of randomized antimicrobial therapy or addition of antifungal therapy, microbiologically defined infections and radiologically confirmed pneumonias. In both included studies, unfavourable outcome led to consideration of adjustment of antimicrobial treatment in both treatment groups and rehospitalization in the early (in Santolaya 2004) or very early (in Brack 2012) discharge group. The criteria used in both studies were relatively objective parameters, which seemed to be adequate. However, in our opinion, fever for more than two to four days is not adequate as a parameter for treatment failure as it can also be caused by a viral infection. Therefore, we did not mention it as an item in our outcome criteria. Finally, we valued rehospitalization or adjustment of antimicrobial treatment (or both) related to febrile neutropenia and death as adequate parameters of treatment failure, for both the in-hospital and the outpatient treatment group.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
The current available evidence, however fairly limited, did not show that early discharge of children with cancer and febrile neutropenia and low risk of bacterial infection was less safe than nonearly discharge, or that very early discharge of children with cancer and febrile neutropenia and low risk of bacterial infection was less safe than early discharge in a carefully selected, carefully instructed and well-monitored group. However, it should be taken into account that the included studies were relatively small, thus the non-significant differences could be due to, for example, a lack of power. There was a significant reduction of costs for the early discharge group in comparison to the non-early discharge group, which could be different in other countries and thus needs to be evaluated by other research groups.
The two available studies provided very limited evidence about the effects of very early discharge and early discharge. The lack of evidence to inform practice decisions justifies the evaluation of these discharge strategies in a trial setting in hospitals/oncology wards where close monitoring of very early and early discharged participants by well-trained employees is guaranteed.
Implications for research
Further research in large randomized controlled trials is required to confirm or contradict that early discharge is not less safe than non-early discharge, and that very early discharge is not less safe than early discharge. In our opinion, it would also be valuable to have more information on quality of life, costs and duration of treatment. In addition, at this time, it is not clear which low-risk criteria are superior, and future studies should address this matter with the objective of establishing uniform low-risk criteria.
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Brack 2012
Methods Randomized controlled trial Study design: parallel group Participants Children with cancer presenting with febrile neutropenia after non-myeloablative chemotherapy Age: 1-18 years The study enrolled 52 children with a total of 62 episodes with low risk of adverse events Children at low risk fulfilled 10 pre-defined low-risk criteria, and 6 additional criteria regarding continuity of supportive therapy, and applicability of oral antimicrobial treatment Low-risk criteria • Diagnosis not acute myeloid leukaemia/mature B acute lymphoid leukaemia/nonHodgkin lymphoma
• Bone marrow involvement < 25%
• No arterial hypotension (mean arterial blood pressure < 50 mm Hg (aged < 10 years)/< 60 mm Hg (aged ≥ 10 years))
• No hypo-oxygenation (SpO 2 < 94% at ambient air)
• No radiologically defined pneumonia • No known allergy to ciprofloxacin/amoxicillin • Serum creatinine level below upper limit of normal range • Able to swallow oral medication Definition of neutropenia: ANC ≤ 500/µL Definition of fever: axillary recording of ≥ 38.5°C once or ≥ 38.0°C during ≥ 2 hours Sex: very early discharge 41% boys; early discharge 44% boys ANC < 100/µL at presentation (%); very early discharge 72%; early discharge 47% Type of malignancy (%): acute lymphoblastic leukaemia; very early discharge 48%; early discharge 53%. Tumour of the central nervous system; very early discharge 11%; early discharge 12%. Solid tumour outside the central nervous system; very early discharge 41%; early discharge 35%
Interventions
After 8-22 hours of inpatient therapy, children who fulfilled low-risk criteria were randomized to very early discharge or early discharge. Children randomized to very early discharge were given a combination of oral ciprofloxacin plus oral amoxicillin, and were discharged within 9-24 hours from presentation with febrile neutropenia. These children were rehospitalized in case of fever ≥ 38.0°C within ≥ 5 days from presentation with febrile neutropenia, and in case of shaking chills, toxic appearance, new signs of local infection or any other reason for inpatient management as determined by the treating physician. Discharge criteria for children randomized to early discharge were absence of fever ≥ 38.0°C for ≥ 48 hours, of toxic appearance and of any other reason for inpatient management as determined by the treating physician. In both groups, modification of therapy was suggested in case of bacteraemia known after re-assessment, signs and symptoms of a local infection, toxic appearance or adverse event/intolerance requiring its discontinuation. Criteria for ending antibiotics were no fever ≥ 38.0°C for 48 hours, an ANC > 500/µL or rising for ≥ 48 hours, no bacteraemia, no local infection and no toxic appearance
Outcomes
Primary outcomes
• Treatment failure; rehospitalization or adjustment of antimicrobial treatment (or both)
• Treatment failure; death Secondary outcomes
• Duration of antimicrobial treatment • Duration of intravenous antimicrobial treatment • Duration of oral antimicrobial treatment Notes Follow-up continued daily during antimicrobial therapy, and every second day until the resolution of severe neutropenia (ANC > 500/µL). Minimal required observations for follow-up included history and physical examination at each visit, daily blood cultures if febrile ≥ 38.0°C, and complete blood cell count every second day We contacted the authors of this study because their definition of outcome treatment failure was slightly different from ours, i.e. in the included study fever > 48 hours, bacteraemia, persistent symptoms and signs of local infection, and addition of antifungal therapy were also considered as treatment failures while, in our review, these were not. We asked the authors to specify the reasons for treatment failure of all episodes of which the reason was not stated specifically or clearly in the full-text article, or both. They responded swiftly and provided the requested data • recent (within < 8 days) receipt of chemotherapy Definition of neutropenia: ANC < 500/µL Definition of fever: 1 axillary recording of ≥ 38.5°C or 2 recordings of ≥ 38°C separated by at least 1 hour Sex: early discharge 43% boys; non-early discharge 49% boys Mean ANC at presentation (95% CI); early discharge 146 /µL (111-182); non-early discharge 137 /µL (98-180)
Risk of bias
Interventions
Children were randomised to ambulatory or hospital-based treatment of febrile neutropenia after 24-36 hours after presentation. Low-risk children were discharged from the hospital after 24-36 hours when assigned to the early discharge group and after a mean of 5.3 days (range 3-9 days) when assigned to the non-early discharge group. After a minimum of 3 days of intravenous antibiotics (ceftriaxone and teicoplanin); either given on the ward for the inpatients or during the daily visit to the oncology clinic for the ambulatory group, the decision to switch to oral antibiotics (cefuroxime axetil) was made on an individual basis, based on pre-defined criteria. Criteria for ending antibiotics were 2 consecutive CRP values ≤ 40 mg/L and 1 full day without fever
Outcomes
Primary outcomes
• Duration of antimicrobial treatment • Duration of intravenous antimicrobial treatment • Duration of oral antimicrobial treatment • Costs Notes Follow-up continued daily until fever resolved and ANC ≥ 500/µL. Daily follow-up consisted of physical examination, CRP measurement, monocyte until they reached 100 /µL and platelet counts until they reached 50,000/µL. For children with a positive culture on admission a repeat culture was obtained at day 3 It should be noted that in this study the used antimicrobial therapy did not meet the Infectious Diseases Society of America Clinical Practice Guidelines recommendations for empiric antimicrobial therapy for febrile neutropenia of the time the study was commenced. The used antimicrobial therapy did not cover for Pseudomonas bacteria, which was the identified micro-organism in the only death in the study febrile AND neutropen* AND child* AND cancer febrile AND neutropen* AND pediatr* AND oncol* fever AND child* AND cancer fever AND pediatr* AND oncol*
Risk of bias
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D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
We changed the 'Primary outcomes' changed from ".... rehospitalization due to febrile neutropenia" to ".... rehospitalization or adjustment of antimicrobial treatment (or both) related to febrile neutropenia (participant deterioration or other febrile neutropeniarelated causes)", as rehospitalization is not a good parameter for treatment failure for people who receive in-hospital treatment. Adjustment of antimicrobial treatment is a more accurate parameter. In addition, we added "patient deterioration or other febrile neutropenia-related causes" between parentheses to emphasize that narrowing of antibiotic therapy when blood culture was known was not as an adverse outcome.
We changed the definition of non-early discharge in the 'Methods' section from "Non-early discharge was defined as discharge from in-hospital treatment after at least five days" to "Non-early discharge as discharge from in-hospital treatment after (a mean or median of ) at least five days", as otherwise important studies comparing of in-hospital treatment might be excluded. For the same reason, we changed "Early discharge from hospital treatment was defined as discharge from the hospital before patients had received five days of in-hospital treatment" was changed to "early discharge as discharge from in-hospital treatment (with a mean or median of ) less than five days after presentation with fever and neutropenia" and "Very early discharge was defined as discharge from in-hospital treatment
